3 mg/m 2 intravenously on days 1, 4, 8, 11, cyclophosphamide
Background The prominent efficacy in terms of increasing progression-free survival (PFS) of Daratumumab, Lenalidomide and dexamethasone (DRd)
Food and Drug Administration (FDA) in 1959, and is still widely used to treat
Will cause death if administered into the spinal fluid
2nd occurrence or platelets remain below 50x109/L for greater than 7 days
Our group has previously published data with HyperCy-Bortezomib-Doxorubicin-Dex (Tabchi et al
In the phase 3 OPTIMISMM trial, pomalidomide, bortezomib, and dexamethasone (PVd) demonstrated superior efficacy vs bortezomib and dexamethasone (Vd) in patients with relapsed or refractory Although no therapies are approved for light chain (AL) amyloidosis, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is considered standard of care
We aimed to assess response-adapted intensification treatment with cyclophosphamide, bortezomib, and dexamethasone (CVD) versus no intensification treatment in patients with newly diagnosed multiple myeloma who had a suboptimal response to initial immunomodulatory triplet treatment which was standard of care in the UK at the time of
Patients received 4–8 induction cycles of bortezomib 1·5 mg/m 2, cyclophosphamide 300 mg/m
Christopher Venner: ELIGIBILITY: Patients must have: Multiple myeloma, plasma cell leukemia, or systemic light chain amyloidosis cyclophosphamide (if using) 500 mg once weekly
KCD therapy was 28 day cycles of biweekly carfilzomib 20/36mg/m 2 IV (weeks 1-3) while VCD was 21 day cycles of biweekly bortezomib 1
Darzalex Faspro® (daratumumab + hyaluronidase-fihj) is a newer formulation of this targeted therapy
3 mg/m intravenously on days 1, 4, 8, 11; dexamethasone
The initial therapy of multiple myeloma (MM) has changed significantly in the past decade because of the introduction of new drugs such as the proteasome inhibitor bortezomib (V) and immunomodulatory drugs (thalidomide, lenalidomide [R])